Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | DDO | Q99489 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SI | P14410 | 2/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509112 | 0.87 | CD44 (0.52) | DAODDOALDH1A1PARP1NPC1 | |
| SCHEMBL4314005 | 0.79 | ACHE (0.46) | ALDH1A1PARP1HPGDRAB9ANPSR1 | |
| SCHEMBL31033488 | 0.79 | PARP1 (0.56) | DAODDOALDH1A1PARP1NPC1 | |
| SCHEMBL353892 | 0.79 | PARP1 (0.56) | DAODDOALDH1A1PARP1NPC1 | |
| Bromide SCHEMBL11628989 | 0.78 | ACHE (0.45) | ALDH1A1PARP1HPGDRAB9ANPSR1 | |
| Bromide SCHEMBL5318093 | 0.78 | PARP1 (0.55) | DAODDOALDH1A1PARP1NPC1 | |
| SCHEMBL6139156 | 0.76 | PARP1 (0.41) | DAODDOALDH1A1PARP1NPC1 | |
| SCHEMBL22349154 | 0.76 | KDM4E (0.43) | DAOALDH1A1HPGDSMN1; SMN2ATM | |
| SCHEMBL110725 | 0.76 | ALDH1A1 (0.41) | DAODDOALDH1A1PARP1NPC1 | |
| SCHEMBL727229 | 0.76 | ALDH1A1 (0.48) | ALDH1A1PARP1NPC1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979683-B2 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2005-12-27 | — | — | US | disclosed |
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-02-10 | — | — | US | disclosed |
| EP-1309594-B1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2004-12-15 | — | — | EP | disclosed |
| US-6794382-B2 | 6-OXO-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE DERIVATIVES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASE; CARDIOVASCULAR, IMMUNOLOGICAL, RESPIRATORY SYSTEM, AND NEURODEGENERATIVE DISORDER TREATMENT | SANOFI-SYNTHELABO (FR) | 2004-09-21 | — | — | US | disclosed |
| EP-1339719-B1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-20040029866-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2004-02-12 | — | — | US | disclosed |
| US-20030203893-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2003-10-30 | — | — | US | disclosed |
| EP-1339719-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | disclosed |
| EP-1309594-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002042306-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-05-30 | — | — | WO | disclosed |
| WO-2002012239-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-02-14 | — | — | WO | disclosed |
| EP-0328955-B1 | Process for the preparation of imidazole-2-carboxylic acids | BASF AG (DE) | 1995-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, CYP3A7, HDAC7 | DAO 2273/4885DDO 2740/4885ALDH1A1 4006/4885 |
| US-20040029866-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, CBR1, NR3C1 | DAO 2304/4885DDO 2134/4885ALDH1A1 3505/4885 |
| US-20030203893-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, HRH4, CBR1 | DAO 1878/4885DDO 2214/4885ALDH1A1 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.